Timing of IABP initiation and its impact on outcomes in acute myocardial infarction with cardiogenic shock: insights from a bi-center retrospective study - Scorecard - MDSpire
Clinical Scorecard: Influence of IABP Start Timing on Outcomes in Acute Myocardial Infarction with Cardiogenic Shock: Findings from a Bi-Center Retrospective Analysis
At a Glance
Category
Detail
Condition
Cardiogenic Shock (CS) due to Acute Myocardial Infarction (AMI)
Key Mechanisms
Rapidly progressive circulatory collapse and end-organ hypoperfusion
Target Population
Patients aged ≥ 18 years with AMI and CS at admission
Care Setting
Tertiary care heart centers
Key Highlights
Mortality rates in CS exceed 40% despite advances in care
IABP provides modest circulatory support compared to other MCS modalities
Early initiation of MCS may improve survival in CS
Current guidelines recommend IABP for mechanical complications or as a bridge to advanced therapies
The area at risk (AAR) is a critical determinant of therapeutic effectiveness
Guideline-Based Recommendations
Diagnosis
CS defined as systolic blood pressure < 90 mmHg for ≥ 30 min, signs of end-organ hypoperfusion, or need for inotropes/vasopressors
Management
IABP recommended for mechanical complications or as a bridge to advanced therapies
Monitoring & Follow-up
Monitor hemodynamic parameters and laboratory markers during hospitalization
Risks
Mortality and complications associated with CS and AMI
Patient & Prescribing Data
Patients with AMI complicated by CS undergoing pPCI
IABP initiation timing may influence clinical outcomes
Clinical Best Practices
Consider early MCS initiation before irreversible end-organ damage
Assess the area at risk to determine potential benefit from MCS therapies
by Istvan Bojti, Sarolta Bojtine Kovacs, David Kovacs, Antonia Ziegler, Alexander Maier, Dirk Westermann, Miroslaw Ferenc, Attila Csaba Nagy, Kalman Racz, Zsolt Koszegi, Gabor Tamas Szabo
